MASTERINVEST Kapitalanlage GmbH Raises Position in McKesson Corporation $MCK

MASTERINVEST Kapitalanlage GmbH lifted its stake in McKesson Corporation (NYSE:MCK) by 88.1% in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,550 shares of the company’s stock after purchasing an additional 726 shares during the quarter. MASTERINVEST Kapitalanlage GmbH’s holdings in McKesson were worth $1,341,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of MCK. Checchi Capital Advisers LLC raised its holdings in McKesson by 7.6% during the 1st quarter. Checchi Capital Advisers LLC now owns 1,235 shares of the company’s stock valued at $1,069,000 after buying an additional 87 shares during the period. Hillsdale Investment Management Inc. lifted its position in McKesson by 15.1% in the first quarter. Hillsdale Investment Management Inc. now owns 1,525 shares of the company’s stock worth $1,320,000 after buying an additional 200 shares during the last quarter. ABC Arbitrage SA purchased a new position in McKesson during the first quarter worth $425,000. Calamos Wealth Management LLC boosted its stake in McKesson by 0.6% during the first quarter. Calamos Wealth Management LLC now owns 5,587 shares of the company’s stock worth $4,835,000 after buying an additional 36 shares during the period. Finally, Calamos Advisors LLC increased its position in McKesson by 60.2% during the first quarter. Calamos Advisors LLC now owns 48,933 shares of the company’s stock valued at $42,345,000 after acquiring an additional 18,388 shares during the last quarter. Institutional investors own 85.07% of the company’s stock.

McKesson Trading Down 0.8%

Shares of MCK opened at $797.33 on Thursday. The firm has a fifty day moving average price of $767.45 and a 200-day moving average price of $838.22. The firm has a market capitalization of $93.35 billion, a P/E ratio of 20.73, a P/E/G ratio of 1.32 and a beta of 0.31. McKesson Corporation has a 12-month low of $637.00 and a 12-month high of $999.00.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Thursday, May 7th. The company reported $11.69 EPS for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.18% and a negative return on equity of 345.35%. The company had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. During the same quarter last year, the firm posted $10.12 EPS. The firm’s revenue was up 6.0% compared to the same quarter last year. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Analysts predict that McKesson Corporation will post 44.28 earnings per share for the current year.

McKesson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st were given a dividend of $0.82 per share. The ex-dividend date of this dividend was Monday, June 1st. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is 8.53%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Barclays reduced their target price on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Bank of America dropped their price target on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $875.00 price target on shares of McKesson in a report on Friday, May 8th. Citigroup reduced their price objective on shares of McKesson from $975.00 to $945.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. Finally, UBS Group boosted their target price on McKesson from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Fourteen investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, McKesson currently has an average rating of “Moderate Buy” and a consensus target price of $960.53.

Insider Activity at McKesson

In other news, CAO Napoleon B. Rutledge, Jr. sold 133 shares of McKesson stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $764.00, for a total transaction of $101,612.00. Following the completion of the sale, the chief accounting officer owned 632 shares of the company’s stock, valued at approximately $482,848. The trade was a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 2,388 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $761.09, for a total value of $1,817,482.92. Following the completion of the sale, the executive vice president owned 3,090 shares of the company’s stock, valued at $2,351,768.10. The trade was a 43.59% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders sold 28,748 shares of company stock valued at $22,262,035. 0.06% of the stock is owned by insiders.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.